Glaucocalyxin b relieving dyskinesia, inflammation and oxidative stress in parkinson's disease model rats by activating the NRF2/HO-1 pathway
By: Lin, Z
.
Contributor(s): Wang, Yunsu.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2023Edition: Vol.85(4), Jul-Aug.Description: 1092-1098p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical sciencesSummary: To analyze that glaucocalyxin B can alleviate dyskinesia, inflammatory response and oxidative stress
in Parkinson's disease model rats by activating the nuclear factor erythroid 2–related factor 2/heme
oxygenase-1 pathway. 150 adults were divided into 5 groups, namely, the sham operation group (healthy
mice), the Parkinson's group and the low-dose group (Parkinson+20 ng/ml) glaucocalyxin B), the
medium-dose group (Parkinson+40 ng/ml glaucocalyxin B) and high-dose group (Parkinson+60 ng/ml
glaucocalyxin B). The number of adjustment steps, the number of forepaw movements and the number
of positive reactions in each group at 0 d have no difference; on the 3rd d in the Parkinson's group,
dose group were reduced than in the sham operation group; on the 7th d, the number of steps in the
Parkinson's group, and dose groups were reduced than the sham operation group. The tumor necrosis
factor-alpha, interleukin-1 beta and interleukin-6 in the Parkinson's disease group, and dose groups
were raised than those in the sham operation group, while these in the dose groups were reduced than in
the Parkinson's group. The reactive oxidative stress concentration and myeloperoxidase activity of the
Parkinson's group, dose group were raised than those of the sham operation group, while in the dose
group were reduced than the Parkinson's group; superoxide dismutase activity level was reduced than
the sham operation group. The levels of nuclear factor erythroid 2-related factor and heme oxygenase-1
in the Parkinson's group, dose groups were raised than those in the sham operation group, while in
the dose groups were raised than those in the Parkinson's group. Further, in the low, medium and high
dose groups increased with the increase of dose (p<0.05). Glaucocalyxin B can alleviate the dyskinesia
of Parkinson's disease model rats and reduce the inflammatory response and oxidative stress response
in rats, its relevant mechanism via activating the nuclear factor erythroid 2-related factor 2/heme
oxygenase-1 pathway.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2024-0419 |
To analyze that glaucocalyxin B can alleviate dyskinesia, inflammatory response and oxidative stress
in Parkinson's disease model rats by activating the nuclear factor erythroid 2–related factor 2/heme
oxygenase-1 pathway. 150 adults were divided into 5 groups, namely, the sham operation group (healthy
mice), the Parkinson's group and the low-dose group (Parkinson+20 ng/ml) glaucocalyxin B), the
medium-dose group (Parkinson+40 ng/ml glaucocalyxin B) and high-dose group (Parkinson+60 ng/ml
glaucocalyxin B). The number of adjustment steps, the number of forepaw movements and the number
of positive reactions in each group at 0 d have no difference; on the 3rd d in the Parkinson's group,
dose group were reduced than in the sham operation group; on the 7th d, the number of steps in the
Parkinson's group, and dose groups were reduced than the sham operation group. The tumor necrosis
factor-alpha, interleukin-1 beta and interleukin-6 in the Parkinson's disease group, and dose groups
were raised than those in the sham operation group, while these in the dose groups were reduced than in
the Parkinson's group. The reactive oxidative stress concentration and myeloperoxidase activity of the
Parkinson's group, dose group were raised than those of the sham operation group, while in the dose
group were reduced than the Parkinson's group; superoxide dismutase activity level was reduced than
the sham operation group. The levels of nuclear factor erythroid 2-related factor and heme oxygenase-1
in the Parkinson's group, dose groups were raised than those in the sham operation group, while in
the dose groups were raised than those in the Parkinson's group. Further, in the low, medium and high
dose groups increased with the increase of dose (p<0.05). Glaucocalyxin B can alleviate the dyskinesia
of Parkinson's disease model rats and reduce the inflammatory response and oxidative stress response
in rats, its relevant mechanism via activating the nuclear factor erythroid 2-related factor 2/heme
oxygenase-1 pathway.
Click on an image to view it in the image viewer
There are no comments for this item.